Inhibition by interleukin 18 of osteolytic bone metastasis by human breast cancer cells

Anticancer Research

Volumn 19, Issue 5 B, 1999, Pages 4131-4138

  Nakata, Atsushi ^a   Tsujimura, Tohru ^a   Sugihara, Ayako ^a   Okamura, Haruki ^a   Iwasaki, Teruo ^b   Shinkai, Kiyoko ^a,c   Iwata, Nobuo ^a   Kakishita, Eizo ^a   Akedo, Hitoshi ^a,c   Terada, Nobuyuki ^a  

^a HYOGO COLLEGE OF MEDICINE   (Japan)

^b NATIONAL HOSPITAL ORGANIZATION KINKI CHUO CHEST MEDICAL CENTER   (Japan)

^c OSAKA MEDICAL CENTER FOR CANCER AND CARDIOVASCULAR DISEASES   (Japan)

Author keywords

Bone; Breast cancer; Interleukin 18; MDA 231 cell; Metastasis; Osteolysis

Indexed keywords

INTERLEUKIN 18; RECOMBINANT INTERLEUKIN 18; UNCLASSIFIED DRUG;

ANIMAL EXPERIMENT; ANIMAL MODEL; ANIMAL TISSUE; ARTICLE; BONE METASTASIS; BREAST CANCER; CANCER GROWTH; CANCER INCIDENCE; CONTROLLED STUDY; DRUG EFFECT; FEMALE; HUMAN; HUMAN CELL; INTRAPERITONEAL DRUG ADMINISTRATION; MOUSE; NONHUMAN; OSTEOLYSIS; PRIORITY JOURNAL; RADIOGRAPHY; X RAY ANALYSIS;

ANIMALS; ANTINEOPLASTIC AGENTS; BONE NEOPLASMS; BREAST NEOPLASMS; FEMALE; HUMANS; INTERLEUKIN-18; MICE; MICE, INBRED BALB C; MICE, NUDE; NEOPLASM TRANSPLANTATION; OSTEOCLASTS; OSTEOLYSIS; RECOMBINANT PROTEINS; TIME FACTORS; TUMOR CELLS, CULTURED;

EID: 0032762666     PISSN: 02507005     EISSN: None     Source Type: Journal    
DOI: None     Document Type: Article

References (29)

1. Yoneda T, Sasaki A and Mundy GR: Osteolytic bone metastasis in breast cancer. Breast Cancer Res Treat 32: 73-84, 1994.
2. Yoneda T: Cellular and Molecular mechanisms of breast and prostate cancer metastasis to bone. Eur J Cancer 34: 240-245, 1998.
3. Guise TA and Mundy GR: Cancer and bone. Endocr Rev 19: 18-54, 1998.
4. Taube T, Elomaa I, Blomqvist C, Beneton MN and Kanis JA: Histomorphometric evidence for osteoclast-mediated bone resorption in metastatic breast cancer. Bone 15: 161-166, 1994.
5. Bouizar Z, Spyratos F, Deytieux S, Vernejoul M-C and Jullienne A: Polymerase chain reaction analysis of parathyroid hormone-related protein gene expression in breast cancer patients and occurence of bone metastases. Cancer Res 53: 5076-5078, 1993.
6. Iezzoni JC, Bruns ME, Frierson HF, Scott MG, Pence RA, Pence BS, Deftos LJ and Bruns DE: Coexpression of parathyroid hormone-related protein and its receptor in breast carcinoma: A potential autocrine effector system. Mod Pathol 11: 265-270, 1998.
7. Guise TA, Yin JJ, Taylor SD, Kumagai Y, Dallas M, Boyce BF, Yoneda T and Mundy GR: Evidence for a causal role of parathyroid hormone-related protein in the pathogenesis of human breast cancer-mediated osteolysis. J Clin Invest 98: 1544-1549, 1996.
8. Sasaki A, Boyce BF, Story B, Wright KR, Chapman M, Boyce R, Mundy GR and Yoneda T: Bisphosphonate risedronate reduces metastatic human breast cancer burden in bone in nude mice. Cancer Res 55: 3551-3557, 1995.
9. Yoneda T, Sasaki A, Dunstan C, Williams PJ, Bauss F, De Clerck YA and Mundy GR: Inhibition of osteolytic bone metastasis of breast cancer by combined treatment with the hisphosphonate ibandronate and tissue inhibitor of the matrix metalloproteinase-2. J Clin Invest 99: 2509-2517, 1997.
10. Fleisch H: Bisphosphonates: mechanisms of action. Endocr Rev 19: 80-100, 1998.
11. Okamura H, Tsutsui H, Komatsu T, Yutsudo M, Hakura A, Tanimoto T, Torigoe K, Okura T, Nukada Y , Hattori K, Akita K, Namba M, Tanabe F, Konishi K, Fukuda S and Kurimoto M: Cloning of a new cytokine that induces IFN-γ production by T cells. Nature 378: 88-91, 1995.
12. Ushio S, Namba M, Okura T, Hattori K, Nukada Y, Akita K, Tanabe F, Konishi K, Micallef M, Fujii M, Torigoe K, Tanimoto T, Fukuda S, Ikeda M, Okamura H and Kurimoto M: Cloning of the cDNA for human IFN-γ -inducing factor,expression in Escherichia coli, and studies on the biologic activities of the protein. J Immunol 156: 4274-4279, 1996.
13. Micallef MJ, Ohtsuki T, Kohno K, Tanabe F, Ushio S, Namba M, Tanimoto T, Torigoe K, Fujii M, Ikeda M, Fukuda S and Kurimoto M: Interferon-γ-inducing factor enhances T helper 1 cytokine production by stimulated human T cells: synergism with interleukin-12 for interferon-γ production. Eur J Immunol 26: 1647-1651, 1996.
14. Tsutsui H, Nakanishi K, Matsui K, Higashino K, Okamura H, Miyazawa Y and Kaneda K: IFN-γ-inducing factor up-regulates Fas ligand-mediated cytotoxic activity of murine natural killer cell clones. J Immunol 157: 3967-3973, 1996.
15. Kohno K, Kataoka J, Ohtsuki T, Suemoto Y, Okamoto I, Usui M, Ikeda M and Kurimoto M: INF-gamma-inducing factor (IGIF) is a costimulatory factor on the activation of Th 1 but not Th 2 cells and exerts its effect independently of IL-I2. J Immunol 158: 1541-1550, 1997.
16. Yoshimoto T, Okamura H, Tagawu YI, Iwakura Y and Nakanishi K: Interleukin 18 together with interleukin 12 inhibits IgE production by induction of interferon-gamma production from activated B cells. Proc Natl Acad Sci USA 94: 3948-3953, 1997.
17. Matsumoto S, Tsuji-Takayama K, Aizawa Y, Koide K, Takeuchi M, Ohta T and Kurimoto M: Interleukin-18 activates NF-kB in murine T helper type 1 cells. Biochem Biophys Res Commun 234: 454-457, 1997.
18. + human blood mononuclear cells. J Clin Invest 101: 711-721, 1998.
19. Micallef MJ, Yoshida K, Kawai S, Hanaya T, Kohno K, Arai S, Tanimoto T, Torigoe K, Fujii M, Ikeda M and Kurimoto M: In vivo antitumor effects of murine interferon-γ-inducing factor/interleukin-18 in mice bearing syngeneic Meth A sarcoma malignant ascites. Cancer Immunol Immunother 43: 361-367, 1997.
20. Micallef MJ, Tanimoto T, Kohno K, Ikeda M and Kurimoto M: Interleukin 18 induces the sequential activation of natural killer cells and cytotoxic T lymphocytes to protect syngeneic mice from transplantation with Meth A sarcoma. Cancer Res 57: 4557-4563, 1997.
21. Ohtsuki T, Micallef MJ, Kohno K, Tanimoto T, Ikeda M and Kurimoto M: Interleukin 18 enhances Fas ligand expression and induces apoptosis in Fas-expressing human myelomonocytic KG-1 cells. Anticancer Res 17: 3253-3258, 1997.
22. Fukumoto H, Nishio M, Nishio K, Heike Y, Arioka H, Kurokawa H, Ishida T, Fukuoka K, Nomoto T, Ohe Y and Saijo N: Interferon-γ-inducing factor gene transfection into Lewis lung carcinoma cells reduces tumorigenicity in vivo. Jpn J Cancer Res 88: 501-505, 1997.
23. Tan J, Crucian BE, Chang AE, Aruga E, Aruga A, Dovhey SE, Tanigawa K and Yu H: Interferon-gamma-inducing factor elicits antitumor immunity in association with interferon-γ production. J Immunother 21: 48-55, 1998.
24. Coughlin CM, Salhany KE, Wysocka M, Aruga E, Kurzawa H, Chang AE, Hunter CA, Fox JC, Trinchieri G and Lee WMF: Interleukin-12 and interleukin-18 synergistically induce murine tumor regression which involves inhibition of angiogenesis. J Clin Invest 101: 1441-1452, 1998.
25. Udagawa N, Horwood NJ, Elliott J, Mackay A, Owens J, Okamura H, Kurimoto M, Chambers TJ, Martin TJ and Gillespie MT: Interleukin-18 (interferon-γ-inducing factor) is produced by osteoblasts and acts via granulocyte/macrophage colony-stimulating factor and not via interferon-γ to inhibit osteoclast formation. J Exp Med 185: 1005-1012, 1997.
26. Horwood NJ, Udagawa N, Elliot J, Grail D, Okamura H, Kurimoto M, Dunn AR, Martin TJ and Gillespie MT: Interleukin 18 inhibits osteoclast formation via T cell production of granulocyte macrophage colony-stimulating factor. J Clin Invest 101: 595-603, 1998.
27. G-nitro-L-arginine methyl ester inhibits bone metastasis after modified intracardiac injection of human breast cancer cells in a nude mouse model. Jpn J Cancer Res 88: 861-866, 1997.
28. Arguello F, Baggs RB and Frantz CNA: A murine model of experimental metastasis to bone and bone marrow. Cancer Res 48: 6876-6881, 1988.
29. v). Cancer Res 52: 2304-2309, 1992.